PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera

Дата публикации: 26-06-2026 01:06:00

BURLINGTON, Mass, June 26, 2026 – PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FORUS Therapeutics Inc – Announces Health Canada Approval of BESREMI® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)	0	15.22	06-07-2026
2	FDA Grants Accelerated Approval for Trutakna (atacicept-vymj) for Adult Patients with Primary IgA Nephropathy	0	17.01	07-07-2026
3	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
4	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD	0	15.69	28-05-2026
5	FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva	0	15.91	19-08-2026
6	FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma	0	11.39	13-08-2026
7	FDA Approves Tauklarify (florquinitau F 18 injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease	0	17.62	14-08-2026
8	FDA Approves Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease	0	18.73	26-06-2026
9	Vertex Announces FDA Approval for Expanded Use of Casgevy for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	0	9.35	01-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 13.23. Источник: www.drugs.com.